Archive · 19 Aug 2025
Glenmark Shares Drop Following Q1 Results; ICICI Securities Maintains 'Sell'
Glenmark Pharma's stock price has dropped recently.
The company's recent financial results showed a big jump in profit, but the overall revenue growth was small.
The US arm of Glenmark plans to launch a new drug in the future.
Because of the recent financial performance, the stock has declined.
ICICI Securities has advised selling the stock due to concerns about the company's growth and profits.
The stock is trading below its short-term moving averages but above its longer-term ones, and has declined 14% from its peak.
Glenmark Pharma shares fell for a second straight session, down 2%.
The stock has corrected nearly 14% from its 52-week high.
For Q1, net profit jumped 86.2% to Rs 46.8 crore; revenue grew marginally.
Glenmark's US arm will launch Micafungin for Injection in September 2025.
ICICI Securities maintained a 'SELL' rating due to weak Q1 performance.
- Who
- Glenmark Pharmaceuticals and ICICI Securities.
- What
- Glenmark Pharma's shares declined and ICICI Securities has a 'SELL' rating.
- When
- Shares declined over two consecutive sessions, as of Tuesday.
- Where
- N/A
- Why
- Due to weak June quarter performance and lower margins.
Glenmark Performance
ICICI Securities
Q1 Performance
Glenmark Performance
Weak Q1 performance
ICICI Securities
N/A
- Share Price Decline (2 Days)
- 5%
- 52-Week High Correction
- 14%
- Q1 Net Profit
- Rs 46.8 crore
- Q1 Revenue Growth
- 0.6%
- Micafungin Launch (US)
- September 2025
- ICICI Securities Rating
- SELL
